




Contents lists available at ScienceDirect

# Bioorganic & Medicinal Chemistry Letters

journal homepage: [www.elsevier.com/locate/bmcl](http://www.elsevier.com/locate/bmcl)

## Design, synthesis and biological evaluation of azithromycin glycosyl derivatives as potential antibacterial agents



Lei Zhang<sup>a,b,†</sup>, Xiaoyun Chai<sup>a,†</sup>, Baogang Wang<sup>a</sup>, Shichong Yu<sup>a</sup>, Honggang Hu<sup>a</sup>, Yan Zou<sup>a</sup>, Qingjie Zhao<sup>a</sup>, Qingguo Meng<sup>b,\*</sup>, Qiuye Wu<sup>a,\*</sup>

<sup>a</sup> Department of Organic Chemistry, School of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, China

<sup>b</sup> Department of Medicinal Chemistry, School of Pharmacy, Yantai University, 30 Qingquan Road, Yantai 264005, China

### ARTICLE INFO

#### Article history:

Received 13 June 2013

Revised 15 July 2013

Accepted 17 July 2013

Available online 25 July 2013

#### Keywords:

Azithromycin

Antibacterial activity

Glycosyl

Synthesis

### ABSTRACT

A series of 11,12-cyclic carbonate azithromycin-4''-O-carbamoyl glycosyl derivatives were designed, synthesized, and evaluated as antibacterial agents to search for target compounds with excellent activity. The results of preliminary antibacterial tests against eight strains in vitro revealed that all of the title compounds exhibited improved activities with broad spectrum compared with the parent compound. The glycosylated side chains may be the pharmacophores responsible for the improved activity.

© 2013 Elsevier Ltd. All rights reserved.

Over the past decade, macrolide antibiotics have played an important role in the clinical treatment of upper and lower respiratory tract infections. These antibiotics act by binding to the ribosomal RNA of bacteria. The previous studies provided strong, detailed evidence of this aforementioned interaction at the molecular level via high-resolution X-ray cocrystal structures.<sup>1–4</sup> These X-ray studies demonstrated that macrolides inhibit bacterial protein synthesis by sterically blocking the passage of nascent polypeptides through the exit tunnel of the ribosome.<sup>5</sup>

Macrolide antibiotics, such as erythromycin A (ERY), clarithromycin (CLA), and azithromycin (AZI) (Fig. 1), are widely prescribed clinically. However, these antibiotics have various disadvantages. ERY, a first-generation macrolide, is readily degraded under acidic conditions, thus losing its antibacterial activity;<sup>6</sup> these degraded products are responsible for undesirable gastrointestinal side effects.<sup>7,8</sup> Second-generation macrolides, such as CLA and AZI, have been widely used for respiratory tract infection due to their superior antibacterial activity, pharmacokinetic properties and fewer gastrointestinal side effects compared to ERY.<sup>9</sup> However, their clinical uses have been limited by the emergence of drug resistance.<sup>10</sup> The increasing incidence of bacterial resistance is becoming a major threat to the successful treatment of infectious diseases. The most serious threat is the increasing resistance of community-acquired

respiratory tract infections to various antimicrobials, which is a pandemic phenomenon.<sup>11</sup> Third-generation macrolide ketolides, such as telithromycin, can effectively address bacterial resistance and other issues associated with current macrolide regimens.<sup>12,13</sup> However, the use of telithromycin suffers from limitations such as hepatotoxicity.<sup>14</sup>

With the widespread emergence of antibacterial resistance against macrolides, there is still a need to develop and extend safe chemotherapeutic agents with potent antibacterial activity. Recently, considerable efforts have been focused on discovering novel macrolides to combat the resistance. Research has indicated that compounds containing particular groups in the 4''-position of the cladinose sugar were effective against macrolide resistant strains.<sup>15</sup> Additionally, the C-11,12 carbamate side chain of macrolides may aid in interactions with the target enzyme.<sup>16</sup> So, we have chosen the 4''-position of the cladinose sugar as the modification position.

Glycosyl moieties exist extensively in organisms and exhibit a variety of biological functions, such as diagnostic and therapeutic potential. D-desosamine and L-cladinose, the two monosaccharides in macrolide structures, are important for the binding of macrolides to ribosomes. X-ray analyses of macrolides have revealed that the hydroxy group of a glycosyl moiety was important for hydrogen bond formation.<sup>2</sup> However, there have been few reports about glycosylation modification of macrolide antibiotics.<sup>17,18</sup> As we believe that the glycosylation may help for the hydrogen bond formation, we therefore introduced glycosyl moieties to AZI through a carbamoyl group and examined the antibacterial activities of the resultant products.

\* Corresponding authors. Tel./fax: +86 21 81871225. (Q.W.).

E-mail addresses: [qinggmeng@163.com](mailto:qinggmeng@163.com) (Q. Meng), [wuqy640319@163.com](mailto:wuqy640319@163.com) (Q. Wu).

† These authors contributed equally to this work.

By substitution of the 4''-position with various carbamoyl-groups, a series of novel 4''-substituted azithromycin derivatives were obtained. Further modification at 11,12-cyclic carbonate azithromycin was performed. We hypothesized that the 11,12-cyclic carbonate azithromycin-4''-O-carbamoyl glycosyl derivatives might enhance the antibacterial activity against resistant strains.

Eight glycosylated intermediates **1f–8f** were prepared from the corresponding commercially available saccharides by following a series of established transformations. We have chosen **1f** as an example (Scheme 1). First, all the hydroxyl groups of glucose (**1a**) were protected with acetyl groups to give the acetylated saccharide (**1b**) in an excellent yield. The treatment of **1b** with 2-azidoethanol in the presence of  $\text{BF}_3 \cdot \text{Et}_2\text{O}$  afforded a series of protected azidoethyl-glycosides (**1c**) in the  $\beta$ -configuration with a very good yield. After deprotection of **1c**, we obtained the azidoethyl-glycosides (**1d**). Compound **1d** was protected with benzyl groups to give the benzylated saccharide (**1e**) in an excellent yield. Lastly, **1e** was reduced by  $\text{Pd}/\text{CaCO}_3$  under a hydrogen atmosphere. The other seven glycosylated intermediates (**2f–8f**) were synthesized in the same manner.

The general synthetic methodology for preparing the compounds of interest (**F1–F8**) is outlined in Scheme 2. Protection of the 2'-hydroxyl group of azithromycin with acetic anhydride provided 2'-acetyl azithromycin (**B**) in 82% yield. 11,12-Cyclic carbonate azithromycin 4''-O-acylimidazole (**C**) was obtained in 62% yield by treatment of compound **B** with  $\text{NaH}$  and  $N,N'$ -carbonyldiimidazole (CDI) in DMF. Then, the intermediates (**D1–D8**) were prepared by coupling compound **C**, followed by benzyl protection of the glycosylated group in the presence of 1,8-diazabicyclo [5.4.0] undec-7-ene (DBU). Lastly, intermediates **D1–D8** were reduced by 10%  $\text{Pd-C}$  under a hydrogen atmosphere. After methanolysis, we obtained compounds **F1–F8**. The yields were within the range of 70–80%.

The in vitro antibacterial activities were reported as minimum inhibitory concentrations (MICs), which were determined using standard dilution assay as recommended by the NCCLS (National

Committee of Clinical Laboratory Standard).<sup>19</sup> The  $\text{MIC}_{80}$  was defined as the first well with an approximate 80% reduction in growth compared to the growth of the drug-free well. For the assays, the title compounds to be tested were dissolved in dimethyl sulfoxide (DMSO), serially diluted in growth medium, inoculated and incubated at 35 °C.

The selected strains evaluated were methicillin-susceptible *Staphylococcus aureus* MSSA-1 (*S. aureus* MSSA-1), methicillin-resistant *Staphylococcus aureus* MRSA-1 (*S. aureus* MRSA-1), *Staphylococcus aureus* ATCC25923 (*S. aureus* ATCC25923), *Streptococcus pneumoniae* 943 (*S. pneumoniae* 943), *Staphylococcus pneumoniae* 746 (*S. pneumoniae* 746), *Streptococcus pyogenes* 447 (*S. pyogenes* 447), *Escherichia coli* 236 (*E. coli* 236), and *Escherichia coli* ATCC25922 (*E. coli* ATCC25922). ERY and AZI served as the positive control and were obtained from their respective manufacturers. The results of the assays are summarized in Table 1. The data points express the mean of replicate experiments. All of our susceptibility tests were performed three times using each antibacterial agent.

The results indicated that nearly all of the 11,12-cyclic carbonate azithromycin-4''-O-carbamoyl glycosyl derivatives showed moderate activity against all the strains, and some of the derivatives exhibited improved activity compared with AZI and ERY. Notably, the  $\text{MIC}_{80}$  values indicate that compounds **F1** and **F2** showed improved activity against all of the bacterial strains relative to the other compounds, expressing the same or higher antibacterial activities as AZI. Compounds **F7** and **F8** with the disaccharide side chain showed the least activity; this observation could be due to increasing side chain length. Among the compounds tested, Compounds **F1** and **F6** showed the same activity against the *S. aureus* MSSA-1 as AZI, and they exhibited eightfold higher activity than ERY. Particularly, compounds **F1** and **F2** showed fourfold and eightfold higher activity against the *S. pneumoniae* 943 than AZI and ERY, respectively. In addition, the activity of compounds **F1** and **F2** ( $\text{MIC}_{80}$  2  $\mu\text{g}/\text{mL}$ ) increased significantly against *S. pneumoniae* 746, showing eightfold higher activity than ERY. The activity of compounds






Figure 1. The structures of macrolide antibiotics.



Scheme 1. The synthesis of the saccharide intermediates. Reactions and conditions: (a)  $\text{Ac}_2\text{O}$ ,  $\text{CH}_3\text{COONa}$ , reflux, 5 h, in 90% yield; (b)  $\text{HOCH}_2\text{CH}_2\text{N}_3$ ,  $\text{BF}_3 \cdot \text{Et}_2\text{O}$ , DCM, Ar, 0 °C, 18 h, in 80% yield; (c)  $\text{CH}_3\text{ONa}$ ,  $\text{CH}_3\text{OH}$ , 4 h, in 93% yield; (d)  $\text{BnBr}$ ,  $\text{NaH}$ , TBAI, DMF, in 52% yield; and (e)  $\text{Pd}/\text{CaCO}_3$ ,  $\text{H}_2$ ,  $\text{CH}_3\text{OH}$ , in 98% yield.



**Scheme 2.** The synthesis of the compounds of interest. Reactions and conditions: (a)  $\text{Ac}_2\text{O}$ , DCM,  $\text{Et}_3\text{N}$ , rt, 24 h, in 82% yield; (b) CDI, NaH, DMF, rt, 24 h, in 62% yield; (c)  $\text{R}'\text{OCH}_2\text{CH}_2\text{NH}_2$ , DMF, DBU, rt, 12 h, in 21–38% yield; (d) Pd/C,  $\text{H}_2$ ,  $\text{CH}_3\text{OH}$ , in 75–88% yield; and (e)  $\text{CH}_3\text{OH}$ , 55 °C, 20 h, 70–80% yield.

**Table 1**

Antibacterial activities of the title compounds in vitro ( $\text{MIC}_{80}$ ,  $\mu\text{g/mL}$ )

Compd	<i>S. aureus</i> MSSA-1	<i>S. aureus</i> MRSA-1	<i>S. aureus</i> ATCC25923	<i>S. pneumoniae</i> 943	<i>S. pneumoniae</i> 746	<i>S. pyogenes</i> 447	<i>E. coli</i> 236	<i>E. coli</i> ATCC25922
<b>F1</b>	2	16	8	1	2	16	64	128
<b>F2</b>	4	32	32	1	2	64	128	128
<b>F3</b>	8	8	8	4	4	32	64	128
<b>F4</b>	16	16	8	2	4	16	64	256
<b>F5</b>	8	8	4	4	8	64	64	128
<b>F6</b>	2	8	16	4	8	64	128	128
<b>F7</b>	16	16	32	8	16	32	128	256
<b>F8</b>	32	32	16	8	16	64	128	256
AZI	2	16	16	4	8	32	256	256
ERY	16	16	16	8	16	32	256	256

**F1** and **F2** against *E. coli* 236 and *E. coli* ATCC25922 was either maintained or slightly greater.

In conclusion, an efficient method has been developed for the synthesis of 11,12-cyclic carbonate azithromycin-4''-O-car-

bamoyl glycosyl derivatives. The results of preliminary antibacterial tests against eight strains in vitro demonstrated that these derivatives exhibited improved activities with a broad spectrum compared with the parent compound, which could be attributed to the glycosylated side chains. The monosaccharide side chain may help the target compounds fit into the binding pocket and interact with the bacterial ribosome. However, compounds **F7** and **F8** with disaccharide side chains expressed the lowest activity, indicating that the bulky disaccharide side chain might hinder the interactions of the derivative with the bacterial ribosome. This study has led to the discovery of a series of compounds for further optimization.

### Acknowledgments

This work was supported by the Major Project of the Science and Technology Ministry of China (No. 2012ZX09502001-005) and by Shanghai Leading Academic Discipline Project Number: B906.

### Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.bmcl.2013.07.042>.

### References and notes

1. Takashima, H. *Curr. Top. Med. Chem.* **2003**, 3, 991.
2. Schlünzen, F.; Zarivach, R.; Harms, J.; Bashan, A.; Tocilj, A.; Albrecht, R.; Yonath, A.; Franceschi, F. *Nature* **2001**, 413, 814.
3. Schlunzen, F.; Harms, J. M.; Franceschi, F.; Hansen, H. A.; Bartels, H.; Zarivach, R.; Yonath, A. *Structure* **2003**, 11, 329.
4. Berisio, R.; Harms, J.; Schlunzen, F.; Zarivach, R.; Hansen, H. A.; Fucini, P.; Yonath, A. *J. Bacteriol.* **2003**, 185, 4276.
5. Hanson, J. L.; Ippolito, J. A.; Ban, N.; Nissen, P.; Moore, P. B.; Steitz, T. A. *Mol. Cell.* **2002**, 10, 117.
6. Atkins, P. J.; Herbert, T. O.; Jones, N. B. *Int. J. Pharm.* **1986**, 30, 199.
7. Itoh, Z.; Nakaya, M.; Suzuki, T.; Aria, H.; Wakabayashi, K. *Am. J. Physiol.* **1984**, 247, G688.
8. Omura, S.; Tsuzuki, K.; Sunazuka, T.; Marui, S.; Toyoda, H.; Inatomi, N.; Itoh, Z. *J. Med. Chem.* **1993**, 1987, 30.
9. Zhanel, G. G.; Dueck, M.; Hoban, D. J.; Vercaigne, L. M.; Embil, J. M.; Gin, A. S.; Karlowsky, J. A. *Drugs* **2001**, 61, 443.
10. Chu, D. T.; Plattner, J. J.; Katz, L. J. *Med. Chem.* **1996**, 39, 3853.
11. Felmingham, D.; Grüneberg, R. N. *J. Antimicrob. Chemother.* **2000**, 45, 191.
12. Zhanel, G. G.; Walters, M.; Noreddin, A.; Vercaigne, L. M.; Wierzbowski, A.; Embil, J. M.; Gin, A. S.; Douthwaite, S.; Hoban, D. J. *Drugs* **2002**, 62, 1771.
13. Bax, R. P.; Anderson, R.; Crew, J.; Fletcher, P.; Johnson, T.; Kaplan, E.; Knaus, B.; Kristinsson, K.; Malek, M.; Strandberg, L. *Nat. Med.* **1998**, 4, 545.
14. Wu, Y. J. *Curr. Pharm. Des.* **2000**, 6, 181.
15. Ma, S. T.; Jiao, B.; Liu, Z. P.; Wang, H.; Xian, R. Q.; Zheng, M. J.; Lou, H. X. *Bioorg. Med. Chem. Lett.* **2009**, 19, 1698.
16. Champney, W. S.; Tober, C. L. *Curr. Microbiol.* **2001**, 42, 203.
17. Liang, C. H.; Yao, S.; Chiu, Y. H.; Leung, P. Y.; Robert, N.; Seddon, J.; Sears, P.; Hwang, C. K.; Ichikawa, Y.; Romero, A. *Bioorg. Med. Chem. Lett.* **2005**, 15, 1307.
18. Xu, P.; Chen, X. Z.; Liu, L.; Jin, Z. P.; Lei, P. S. *Bioorg. Med. Chem. Lett.* **2010**, 20, 5527.
19. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 5th ed.; Approved Standard: NCCLS Document M7-A5; **2000**, 20(2).